Table 3:
Univariate analysis of center characteristics and 1-year survival
| Centers, N | Patients, N | 1-year survival, % | P-value* | |
|---|---|---|---|---|
| Affiliation with teaching hospital | 0.724 | |||
| No | 15 | 807 | 60.7 | |
| Yes | 68 | 10730 | 61.0 | |
| Ownership status | 0.580 | |||
| Government | 22 | 2748 | 59.3 | |
| Private | 61 | 8789 | 61.5 | |
| Hospital size (inpatient beds) | 0.624 | |||
| <500 | 30 | 3705 | 63.0 | |
| 500–999 | 42 | 6240 | 60.4 | |
| ≥1000 | 11 | 1592 | 58.4 | |
| NCI Comprehensive Cancer Center | 0.295 | |||
| No | 46 | 3731 | 59.2 | |
| Yes | 37 | 7806 | 61.8 | |
| EHR in inpatient and/or outpatient area | 0.725 | |||
| No | 6 | 477 | 60.2 | |
| Yes | 77 | 11060 | 61.0 | |
| Inpatient beds exclusively dedicated to HCT | 0.327 | |||
| No | 6 | 473 | 56.7 | |
| Yes | 77 | 11064 | 61.2 | |
| Separate outpatient clinic for HCT patients | 0.581 | |||
| No | 29 | 2752 | 60.2 | |
| Yes | 54 | 8785 | 61.2 | |
| Stem cell processing lab on site/campus | 0.852 | |||
| No | 9 | 641 | 61.5 | |
| Yes | 74 | 10896 | 60.9 | |
| FACT accreditation for allogeneic HCT | 0.766 | |||
| No | 5 | 93 | 58.1 | |
| Yes | 78 | 11444 | 61.0 | |
| Participation in cooperative group clinical trials | 0.832 | |||
| No | 14 | 538 | 60.4 | |
| Yes | 69 | 10999 | 61.0 | |
| Patients enrolled on IRB approved protocols | 0.471 | |||
| None | 4 | 120 | 52.5 | |
| <25% | 34 | 2895 | 60.7 | |
| 25–49% | 25 | 5274 | 60.6 | |
| ≥50% | 20 | 3248 | 62.1 | |
| Affiliated with hematology-oncology fellowship program | 0.994 | |||
| No | 17 | 893 | 61.9 | |
| Yes | 66 | 10644 | 60.9 | |
| Long-term follow-up or survivorship program | 0.005 | |||
| No | 55 | 5941 | 58.0 | |
| Yes | 28 | 5596 | 64.1 | |
| Graft-versus-host disease clinic | 0.013 | |||
| No | 68 | 7577 | 59.4 | |
| Yes | 15 | 3960 | 64.0 | |
| Average inpatient nurse-patient ratio | 0.247 | |||
| ≤1:2 | 20 | 1520 | 62.7 | |
| 1:3 | 51 | 7833 | 61.7 | |
| ≥1:4 | 12 | 2184 | 57.1 | |
| FTE transplant clinical coordinators | 0.034 | |||
| ≤1 | 9 | 302 | 64.9 | |
| 2–3 | 36 | 2385 | 56.3 | |
| 4–6 | 29 | 5561 | 62.4 | |
| ≥7 | 9 | 3289 | 61.5 | |
| FTE pharmacists | 0.048 | |||
| ≤1 | 34 | 2123 | 57.2 | |
| 2–3 | 40 | 6440 | 61.1 | |
| ≥4 | 9 | 2974 | 63.4 | |
| FTE psychosocial clinicians | 0.011 | |||
| ≤1 | 31 | 1656 | 56.3 | |
| 2–3 | 44 | 6284 | 60.3 | |
| ≥4 | 8 | 3597 | 64.4 | |
| Clinical effort of majority of HCT physicians | 0.220 | |||
| See HCT patients only | 21 | 4912 | 62.4 | |
| See HCT and hematologic oncology patients | 55 | 6475 | 60.0 | |
| See HCT and general oncology patients | 7 | 150 | 52.7 | |
| Provider responsible for after hour calls | 0.090 | |||
| Attending physician | 50 | 7485 | 62.4 | |
| Fellow | 24 | 2691 | 58.6 | |
| Other providers (e.g., hospitalists, APPs) | 9 | 1361 | 58.1 | |
| Primary team for patients on ventilator | 0.448 | |||
| HCT team | 7 | 970 | 56.0 | |
| Critical care team | 26 | 3042 | 60.5 | |
| Co-managed by HCT and critical care teams | 50 | 7525 | 61.8 | |
| Primary unit for ventilator patients | 0.563 | |||
| HCT unit | 17 | 3228 | 59.4 | |
| Critical care unit | 66 | 8309 | 61.6 | |
| Physician care model in first 100 days | 0.546 | |||
| Same physician inpatient and outpatient | 11 | 344 | 56.0 | |
| >1 physician inpatient and same outpatient | 51 | 7699 | 60.0 | |
| >1 physician inpatient and outpatient | 21 | 3494 | 63.4 | |
| Outpatient care model till day 100 for most patients | 0.236 | |||
| Seen by attending physician | 47 | 5907 | 59.7 | |
| Seen by APPs and staffed with physician | 32 | 4929 | 62.2 | |
| Seen by APPs independently | 4 | 701 | 63.3 | |
| Discharge practice for most patients without complications | 0.383 | |||
| Varies from provider to provider | 50 | 7474 | 61.2 | |
| Co-followed with referring oncologist | 18 | 2873 | 61.9 | |
| Patients are not discharged from transplant center | 15 | 1190 | 57.2 | |
Abbreviations: alloHCT – allogeneic hematopoietic cell transplantation; HCT – hematopoietic cell transplantation; NCI – National Cancer Institute; EHR – electronic health record; FACT: Foundation for the Accreditation of Cellular Therapy; IRB – Institutional Review Board; FTE – full time equivalent
*
P-value for univariate random effect logistic regression analysis